TuisGLSWQ • OTCMKTS
add
Gelesis
Vorige sluiting
$0,00
Markkapitalisasie
7,33 k USD
P/V-verhouding
-
Dividend-opbrengs
-
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Jun. 2023info | J/J-verandering |
|---|---|---|
Inkomste | 1,11 m | — |
Bedryfskoste | 10,60 m | — |
Netto inkomste | -7,68 m | — |
Netto winsgrens | -693,86 | — |
Wins per aandeel | — | — |
EBITDA | -7,93 m | — |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Jun. 2023info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 7,91 m | — |
Totale bates | 95,88 m | — |
Totale aanspreeklikheid | 114,50 m | — |
Totale ekwiteit | -18,62 m | — |
Uitstaande aandele | 73,34 m | — |
Prys om te bespreek | -0,00 | — |
Opbrengs op bates | -25,68% | — |
Opbrengs op kapitaal | -55,33% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Jun. 2023info | J/J-verandering |
|---|---|---|
Netto inkomste | -7,68 m | — |
Kontant van bedrywe | 617,00 k | — |
Kontant van beleggings | -18,00 k | — |
Kontant van finansiering | 4,17 m | — |
Netto kontantverandering | 4,81 m | — |
Beskikbare kontantvloei | 3,82 m | — |
Meer oor
Gelesis is a biotechnology company located in Boston, Massachusetts that developed the weight loss device Gelesis100 for use in overweight and obesity. The company produces Gelesis100, which is a superabsorbent hydrogel capsule that expands in the stomach, creating a feeling of fullness, helping people reduce the amount of food they eat. The company was founded in 2006 to develop medical devices and treatments for obesity.
Gelesis Holdings, Inc. together with its two affiliates, filed for voluntary Chapter 7 liquidation in the United States Bankruptcy Court for the District of Delaware on October 30, 2023. The debtor listed its assets among the 50 and the $100 million and liabilities of $44.34 million. The Debtor is represented by Kenneth Listwak of Troutman Pepper Hamilton Sanders LLP as counsel. Wikipedia
Gestig
2006
Hoofkwartier
Webwerf
Werknemers
93
